Cyclacel Pharmaceuticals, INC 8-K filings

Cyclacel Pharmaceuticals announced its Q1 2025 financial results, highlighting a focus on the plogosertib clinical program and a gain from the deconsolidation of its UK subsidiary.

Cyclacel Pharmaceuticals enacted a 1-for-16 reverse stock split of its common stock, effective May 12, 2025, to comply with Nasdaq's share bid price requirements.

Cyclacel Pharmaceuticals will acquire Fitters Sdn. Bhd., a Malaysian fire safety company, in a share exchange agreement, issuing 19.99% of its common stock to Fitters Diversified Berhad.

Cyclacel Pharmaceuticals amends its certificate of incorporation to increase authorized common stock and removes an ownership limitation on its Series E Convertible Preferred Stock.

Cyclacel Pharmaceuticals declares a $0.15 per share quarterly cash dividend on its 6% Convertible Exchangeable Preferred Stock.

Cyclacel Pharmaceuticals announced its fourth-quarter financial results, focusing on the development of plogosertib and the appointment of two new independent directors.

Cyclacel Pharmaceuticals announced a $1 million private placement offering of convertible Series E Preferred Stock to accredited investors, with proceeds intended for working capital and general corporate purposes.

Cyclacel Pharmaceuticals acquires Plogosertib assets from its UK-based subsidiary, Cyclacel Limited, which is currently in liquidation, for £250,000.

Cyclacel Pharmaceuticals announces a change in control with Datuk Dr. Doris Wong Sing Ee becoming the new CEO and a series of board resignations and appointments.

Cyclacel Pharmaceuticals amended its securities purchase agreement with David Lazar, its interim CEO, to adjust the purchase price and add a six-month lock-up period for shares issued.

Cyclacel Pharmaceuticals modifies its Series C and D Convertible Preferred Stock designations to remove ownership limitations and increases the number of authorized common stock shares.

Cyclacel Pharmaceuticals enters into agreements for potential financing of up to $36 million through securities purchase agreements with David Lazar and Helena Special Opportunities 1 Ltd.

Cyclacel Pharmaceuticals' UK subsidiary, Cyclacel Limited, has entered creditors voluntary liquidation (CVL) as announced in the London Gazette on January 31, 2025, as part of a strategic shift to reduce operating costs and focus on the development of plogosertib.

Cyclacel Pharmaceuticals amended its Securities Purchase Agreement with David E. Lazar to correct an error regarding board appointments.

Cyclacel Pharmaceuticals has entered into an agreement for a $3.1 million investment, with David Lazar becoming interim CEO and the board undergoing a reconstitution.

Cyclacel Pharmaceuticals has been notified by Nasdaq that its common stock has fallen below the minimum bid price requirement, initiating a 180-day grace period to regain compliance.

Cyclacel Pharmaceuticals closed a transaction involving the exercise of existing warrants, generating $2.1 million in gross proceeds and issuing new warrants.

Cyclacel Pharmaceuticals announced its third quarter financial results, highlighting a reduction in operating expenses and a net loss of $2.0 million, while also facing challenges with Nasdaq compliance and funding.

Cyclacel Pharmaceuticals has dismissed Crowe LLP as its independent auditor and engaged Bush & Associates CPA LLP, following concerns about the classification of warrants issued in prior security purchase agreements.

Cyclacel Pharmaceuticals has been granted an extension until December 24, 2024, by Nasdaq to regain compliance with the minimum stockholders' equity requirement.

Cyclacel Pharmaceuticals' board of directors has resolved to suspend the upcoming quarterly cash dividend payment on its 6% Convertible Exchangeable Preferred Stock, scheduled for November 1, 2024.

Cyclacel Pharmaceuticals is facing potential delisting from the Nasdaq due to not meeting the minimum equity requirement, and has requested a hearing to present a plan for regaining compliance.

Cyclacel Pharmaceuticals has received a delisting notice from Nasdaq after failing to maintain the required minimum stockholders' equity, despite a prior equity raise.

Cyclacel Pharmaceuticals has changed its independent auditor, dismissing RSM US LLP and engaging Crowe LLP, effective August 19, 2024.

Cyclacel Pharmaceuticals announced its second quarter financial results, highlighted by increased cash reserves and progress in its fadraciclib clinical trial.

Cyclacel Pharmaceuticals held its annual meeting, approving an amendment to its equity incentive plan and appointing a new board chair, while also suspending a preferred stock dividend.

Cyclacel Pharmaceuticals announced its first quarter financial results, highlighted by the enrollment of first patients in a Phase 2 trial and an $8 million private placement.

Cyclacel Pharmaceuticals has successfully completed an $8 million private placement to bolster its working capital.

Cyclacel Pharmaceuticals' board of directors has resolved to suspend the upcoming quarterly cash dividend payment for its 6% Convertible Exchangeable Preferred Stock, scheduled for May 1, 2024.

Cyclacel Pharmaceuticals received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement of $2.5 million, reporting only $607,000 as of December 31, 2023.